1 |
Barlin JN, Yu C, Hill EK, et al (2012). Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. Gynecol Oncol, 125, 25-30.
DOI
|
2 |
Ciucci A, Zannoni GF, Travaglia D, et al (2014). Prognostic significance of the estrogen receptor beta ( ) isoforms , , and in advanced serous ovarian cancer. Gynecol Oncol, 132, 351-9.
DOI
|
3 |
Chien J, Kuang R, Landen C, et al (2013). Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol, 24, 243-51.
|
4 |
Foley OW, Rauh-Hain JA, del Carmen MG (2013). Recurrent epithelial ovarian cancer: an update on treatment. Oncology, 27, 288-94.
|
5 |
Gonzalez-Martin A (2013). Update on randomized trials on recurrent disease. Ann Oncol, 24, 1-5.
DOI
|
6 |
Harter P, Heitz F, du Bois A (2012). Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep, 14, 539-43.
DOI
|
7 |
Raja FA, Counsell N, Colombo N, et al (2013). Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol, 24, 3028-34.
DOI
|
8 |
Suprasert P, Manopunya M, Cheewakriangkrai C (2014). Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience. Asian Pac J Cancer Prev, 15, 1145-8.
DOI
ScienceOn
|
9 |
Suprasert P, Chalapati W (2013). Detection of recurrence in a surveillance program for epithelial ovarian cancer. Asian Pac J Cancer Prev, 14, 7193-6.
DOI
|
10 |
Suprasert P, Cheewakriangkrai C, Manopunya M (2012). Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma. Asian Pac J Cancer Prev, 13, 517-20.
DOI
ScienceOn
|
11 |
Thigpen T (2012). A rational approach to the management of recurrent or persistent ovarian carcinoma. Clin Obstet Gynecol, 55, 114-30.
DOI
|